Gene Therapy Deals Are Up 1700% in 2026 — Here's the Data

Gene therapy deal activity surged 1700% between the first and second halves of the trailing twelve months — from 2 deals (September 2025 to March 2026) to 36 deals (March 2026 to September 2026). This is not a gradual warming. This is a regime change in how Big Pharma is valuing in vivo genetic medicines, driven by converging clinical validation, next-generation capsid engineering, and a genuine fear among top-10 pharma companies that they will miss the window on durable, one-shot therapeutics.

The Data — Gene Therapy Deal Activity, Period over Period

To put this in context: gene therapy licensing was essentially dormant in the back half of 2025. The modality had been stuck in a credibility trough — manufacturing cost overruns, Bluebird's commercial struggles, and multiple CRLs had spooked both strategic buyers and institutional investors. Two deals in six months is not a market. It's a flatline. The reversal to 36 deals represents one of the sharpest modality surges we've tracked on the Deal Benchmarks platform in any category this year.

What's Driving the Trend

Three forces converged to reignite gene therapy deal trends in 2026. First, clinical proof points accumulated faster than the market priced in. Verve Therapeutics' in vivo base editing data in heterozygous familial hypercholesterolemia transformed the cardiovascular gene therapy thesis from speculative to investable. Lilly didn't pay $1B upfront on a hunch — they paid it because the single-dose LDL reduction data held durability through 18 months. That deal repriced the entire modality. Second, next-generation AAV capsids and non-viral delivery systems have meaningfully de-risked the manufacturing and immunogenicity bottlenecks that killed earlier programs. REGENXBIO's NAV Technology Platform, now partnered with AbbVie, represents a step-change in tissue tropism and reduced neutralizing antibody prevalence. The manufacturing economics are shifting: cost-of-goods projections for optimized AAV vectors have dropped roughly 40–60% compared to first-generation processes, making commercial viability realistic outside ultra-rare diseases. Third, Big Pharma pipeline anxiety is acute. Patent cliffs in 2027–2030 for blockbuster biologics and small molecules are creating strategic urgency. Gene therapy — particularly in cardiovascular, metabolic, and neurology indications — offers something most modalities cannot: the credible promise of one-and-done treatment with lifetime value capture. That narrative, backed by improving clinical data, has unlocked budget from BD committees that were skeptical 18 months ago.

There's also a capital markets dimension. Public biotech gene therapy companies were trading at 3–5 year lows through late 2025, making acquisitions and licensing deals accretive for pharma buyers. Several of the 36 deals in this surge involved biotechs that had limited cash runway and were negotiating from constrained positions. The buyers knew it.

Notable Deals

The Verve–Lilly deal is the anchor transaction of this entire cycle. A $1B upfront with $2.3B in total deal value for an in vivo gene editing cardiovascular program is a landmark. It signals Lilly's conviction that gene therapy has crossed the viability threshold in large-population indications — not just ultra-rare diseases. For Deal Benchmarks purposes, the $1B upfront sets a new ceiling for preclinical-to-Phase 2 gene therapy assets in cardiometabolic targets.

Lilly's back-to-back Engage Bio deals on consecutive days ($200M and $202M TDV) suggest a platform acquisition strategy — securing multiple vectors or targets from the same technology base. This pattern mirrors what we saw in ADC licensing during 2023–2024 and typically indicates the buyer believes the platform itself, not just individual programs, has strategic value.

The MeiraGTx–Oberland Capital deal is structurally different and worth noting. Oberland is a royalty capital firm, not a pharma strategic. A $400M royalty financing deal for a gene therapy company suggests the secondary market for gene therapy cash flows is maturing. When royalty funds underwrite gene therapy revenue streams, it compresses risk perception across the entire modality.

The REGENXBIO–AbbVie partnership, while lacking disclosed financial terms, is strategically significant. AbbVie's post-Humira portfolio needs durable, differentiated assets. Licensing REGENXBIO's capsid platform gives AbbVie optionality across multiple therapeutic areas without the binary risk of a single-program acquisition.

What This Means for BD Teams Right Now

If you are a biotech with a differentiated gene therapy platform — novel capsid, non-viral delivery, or validated in vivo editing — this is the strongest seller's market the modality has seen since 2019. Upfront values are resetting higher. The Verve deal is the new comp, and every gene therapy BD team on the sell side should be anchoring negotiations to it. Use the Ambrosia calculator to benchmark your asset's value against the current deal environment before entering term sheet discussions.

If you are a pharma buyer, recognize that the window on discounted gene therapy assets is closing. The 36-deal surge means competing bids are now the norm, not the exception. Expect licensors to run competitive processes. The most consequential tactical shift: milestone-heavy structures are giving way to larger upfronts. Biotechs that survived the 2024–2025 funding drought learned their lesson — they want cash at signing, not promises tied to Phase 3 readouts they may not have the runway to reach. Buyers who lead with large upfronts and reasonable royalty tiers will win the best assets. Those who try to backload value into milestones will lose processes to competitors willing to pay now.

For investors and royalty funds, the Oberland–MeiraGTx template is likely to be replicated. Gene therapy royalty streams — particularly for approved or late-stage products — are an emerging asset class. Expect more structured financing deals as gene therapy revenues materialize.

Benchmark your deal against current market rates using the Ambrosia calculator. In a 1700% surge environment, negotiating without current comps is negotiating blind.